Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer.

Overexpression of myeloid cell leukemia-1 (Mcl-1) in cancers correlates with high tumor grade and poor survival. Additionally, Mcl-1 drives intrinsic and acquired resistance to many cancer therapeutics, including B cell lymphoma 2 family inhibitors, proteasome inhibitors, and antitubulins. Therefore, Mcl-1 inhibition could serve as a strategy to target cancers that require Mcl-1 to evade apoptosis. Herein, we describe the use of structure-based design to discover a novel compound (42) that robustly and specifically inhibits Mcl-1 in cell culture and animal xenograft models. Compound 42 binds to Mcl-1 with picomolar affinity and inhibited growth of Mcl-1-dependent tumor cell lines in the nanomolar range. Compound 42 also inhibited the growth of hematological and triple negative breast cancer xenografts at well-tolerated doses. These findings highlight the use of structure-based design to identify small molecule Mcl-1 inhibitors and support the use of 42 as a potential treatment strategy to block Mcl-1 activity and induce apoptosis in Mcl-1-dependent cancers.

• Publication year

  2019

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2019-03-30

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/acs.jmedchem.8b01991PMID 30929420
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Optimization of Potent and Selective Tricyclic Indole Diazepinone Myeloid Cell Leukemia-1 Inhibitors Using Structure-Based Design.

  2018cited by this paper
• A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.

  2018cited by this paper
• Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors.

  2017cited by this paper
• Discovery and biological characterization of potent myeloid cell leukemia‐1 inhibitors

  2017cited by this paper
• Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines

  2016cited by this paper
• The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

  2016cited by this paper
• Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods.

  2016cited by this paper
• Discovery of tricyclic indoles that potently inhibit Mcl-1 using fragment-based methods and structure-based design.

  2015cited by this paper
• The BCL-2 protein family, BH3-mimetics and cancer therapy

  2015cited by this paper
• Current approaches in treatment of triple-negative breast cancer

  2015cited by this paper
• Designed BH3 Peptides with High Affinity and Specificity for Targeting Mcl-1 in Cells

  2014cited by this paper
• Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia

  2014cited by this paper
• Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy

  2013cited by this paper
• Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia.

  2013cited by this paper
• ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

  2013cited by this paper
• Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design.

  2013cited by this paper
• Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency.

  2012cited by this paper
• The Discovery of Navitoclax, a Bcl-2 Family Inhibitor

  2012cited by this paper
• Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7

  2011cited by this paper
• The MCL-1 BH3 Helix is an Exclusive MCL-1 inhibitor and Apoptosis Sensitizer

  2010cited by this paper
• A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy

  2010cited by this paper
• The landscape of somatic copy-number alteration across human cancers

  2010cited by this paper
• Bcl‐XL and MCL‐1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis

  2009cited by this paper
• Bcl-2 inhibitors: small molecules with a big impact on cancer therapy

  2009cited by this paper
• Inducing apoptosis and enhancing chemosensitivity to Gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell

  2008cited by this paper
• Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.

  2008cited by this paper
• The Bcl-2 apoptotic switch in cancer development and therapy

  2007cited by this paper
• Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer.

  2007cited by this paper
• Structural insights into the degradation of Mcl-1 induced by BH3 domains

  2007cited by this paper
• Phaser crystallographic software

  2007cited by this paper
• Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells

  2005cited by this paper
• Essential role of BAX,BAK in B cell homeostasis and prevention of autoimmune disease.

  2005cited by this paper
• The antiapoptotic member of the Bcl-2 family Mcl-1 is a CTL target in cancer patients

  2005cited by this paper
• Cell death: critical control points.

  2004cited by this paper
• Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization.

  2004cited by this paper
• Small-molecule inhibitors of protein–protein interactions: progressing towards the dream

  2004cited by this paper
• Structural biology of the Bcl-2 family of proteins.

  2004cited by this paper
• Coot: model-building tools for molecular graphics.

  2004cited by this paper
• Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1

  2003cited by this paper
• Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.

  2002cited by this paper
• Immunohistochemical Analysis of Bcl-2, Bax, Bcl-X, and Mcl-1 Expression in Pancreatic Cancers

  1999cited by this paper
• Three-dimensional structures of proteins involved in programmed cell death.

  1997cited by this paper
• Caspase-dependent apoptosis of COS-7 cells induced by Bax overexpression: differential effects of Bcl-2 and Bcl-xL on Bax-induced caspase activation and apoptosis

  1997cited by this paper
• Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF.

  1997cited by this paper
• Bcl-2 and the regulation of programmed cell death

  1994cited by this paper
• The CCP4 suite: programs for protein crystallography.

  1994cited by this paper

• Synthesis, crystal structure, electronic properties, and molecular docking study of bis [5-imino-7-phenyl-5H-thiazolo[3,2-a] pyrimidine-6-carbonitrile]

  2026cites this paper
• Sphaerindicin: A Novel Anticancer Compound From Hydroethanoli c Extract of Sphaeranthus Indicus Against Lung Adenocarcinoma

  2025cites this paper
• Saga of MCL1 inhibitors in multiple myeloma.

  2025cites this paper
• Discovery of Macrocyclic Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors that Demonstrate Potent Cellular Efficacy and In Vivo Activity in a Mouse Solid Tumor Xenograft Model

  2025cites this paper
• Rhodium(III)-Catalyzed C-H Activation/Annulation of Indoles with Cyclopropanols: A Rapid Assembly of Indole-Fused Diazepinones.

  2025cites this paper
• Recent advances of small-molecule Mcl-1 inhibitors or degraders as promising anti-cancer agents (2018-present).

  2025cites this paper
• Drug design of an anticancer drug: QSAR modeling, and molecular docking

  2025cites this paper
• Recent research progress of β-carbolines as privileged scaffold in the discovery of anticancer agent (2019-2024).

  2025cites this paper
• Augmenting the Anti‐Leukemic Activity of the BCL‐2 Inhibitor Venetoclax Through Its Transformation Into Polypharmacologic Dual BCL‐2/HDAC1 and Dual BCL‐2/HDAC6 Inhibitors

  2025cites this paper
• Directing Group-Controlled Regioselective [4 + 3] Annulation of Indole-2-Carboxamides with MBH Carbonates toward Highly Substituted Indole-1,2-Fused Diazepanones.

  2025cites this paper
• Drugging Challenging Cancer Targets Using Fragment-Based Methods

  2025cites this paper
• Diastereoselective radical cascade cyclization to access indole-fused diazepine derivatives.

  2025cites this paper
• Targeting Myeloid Leukemia-1 in Cancer Therapy: Advances and Directions.

  2024cites this paper
• Chemical dissection of selective myeloid leukemia-1 inhibitors: How they were found and evolved.

  2024cites this paper
• Synthesis of pyrrole-fused dibenzoxazepine/dibenzothiazepine/triazolobenzodiazepine derivatives via isocyanide-based multicomponent reactions

  2024cites this paper
• Discovery of Novel Mcl-1 Inhibitors with a 3-Substituted-1H-indole-1-yl Moiety Binding to the P1-P3 Pockets to Induce Apoptosis in Acute Myeloid Leukemia Cells.

  2024cites this paper
• Discovery of a Myeloid Cell Leukemia 1 (Mcl-1) Inhibitor That Demonstrates Potent In Vivo Activities in Mouse Models of Hematological and Solid Tumors

  2024cites this paper
• Discovery of Phenylpyrazole Derivatives as a New Class of Selective Inhibitors of MCL-1 with Antitumor Activity

  2024cites this paper
• Anti-apoptotic MCL-1 promotes long-chain fatty acid oxidation through interaction with ACSL1.

  2024cites this paper
• Targeting Mitochondria with ClpP Agonists as a Novel Therapeutic Opportunity in Breast Cancer

  2023cites this paper
• Perusal on the role of DMF solvent and hydrogen bonding in the formation of 1D polymeric chains in mixed ligand Ni(II) complex as an anticancer agent: a computational approach

  2023influential citation
• Tetrazole and acylsulfonamide bioisosteric replacements of the carboxylic acid in a dual MCL-1/BCL-xL inhibitor are tolerated

  2023cites this paper
• B‐cell lymphoma‐2 family proteins in the crosshairs: Small molecule inhibitors and activators for cancer therapy

  2023cites this paper
• Targeting MCL-1 triggers DNA damage and an anti-proliferative response independent from apoptosis induction

  2023cites this paper
• A Structure-Guided Designed Small Molecule Is an Anticancer Agent and Inhibits the Apoptosis-Related MCL-1 Protein

  2023cites this paper
• An updated patent review of Mcl-1 inhibitors (2020–2022)

  2023cites this paper
• Discovery of N-sulfonylated aminosalicylic acids as dual MCL-1/BCL-xL inhibitors.

  2023cites this paper
• MCL-1 is a master regulator of cancer dependency on fatty acid oxidation

  2022cites this paper
• Design, synthesis and biological evaluation of hydantoin derivatives as Mcl-1 selective inhibitors.

  2022cites this paper
• MCL-1 is a clinically targetable vulnerability in breast cancer

  2022influential citation
• 1‐Sulfonylated 1,2,3,4‐tetrahydroquinoline‐6‐carboxylic acids as simple, readily‐accessible MCL‐1 inhibitors

  2022cites this paper
• Convenient Synthesis of N-Heterocycle-Fused Tetrahydro-1,4-diazepinones

  2022cites this paper
• Targeting MCL-1 in cancer: current status and perspectives

  2021cites this paper
• A computational perspective for tailor-made selective Mcl-1 and Bcl-XL inhibitors

  2021cites this paper
• Steric-switched defluorofunctionalization selectivity: controlled synthesis of monofluoroalkene-masked medium-sized heterocyclic lactams and lactones

  2021cites this paper
• The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs

  2021cites this paper
• Discovery of 3,5-Dimethyl-4-Sulfonyl-1H-Pyrrole-Based Myeloid Cell Leukemia 1 Inhibitors with High Affinity, Selectivity, and Oral Bioavailability.

  2021cites this paper
• Understanding MCL1: from cellular function and regulation to pharmacological inhibition

  2021cites this paper
• Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma

  2021influential citation
• The interplay between apoptosis and cellular senescence: Bcl-2 family proteins as targets for cancer therapy.

  2021cites this paper
• Modular and Stereoselective Approach to Highly Substituted Indole/Pyrrole-Fused Diazepanones.

  2021cites this paper
• Ten-Year Retrospective of the Vanderbilt Institute of Chemical Biology Chemical Synthesis Core.

  2021cites this paper
• Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia

  2020cites this paper
• Development of Mcl-1 inhibitors for cancer therapy.

  2020cites this paper
• MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents

  2020cites this paper
• Interdiction at a Protein-Protein Interface: MCL-1 Inhibitors for Oncology.

  2020cites this paper
• Discovery of small molecule inhibitors through pharmacophore modeling, molecular docking, molecular dynamics simulation and experimental validation against myeloid cell leukemia-1 (Mcl-1)

  2020cites this paper
• Targeting MCL-1 in hematologic malignancies: Rationale and progress.

  2020cites this paper
• Mcl-1 as a "barrier" in cancer treatment: Can we target it now?

  2020cites this paper
• Design, synthesis and biological evaluation of tyrosine derivatives as Mcl-1 inhibitors.

  2020cites this paper
• Hot-Spots of Mcl-1 Protein.

  2020cites this paper
• Discovery of a Copper-Based Mcl-1 Inhibitor as an Effective Antitumor Agent.

  2020cites this paper
• Discovery of novel indazole-acylsulfonamide hybrids as selective Mcl-1 inhibitors.

  2020cites this paper
• Myeloid cell leukemin-1 inhibitors: a growing arsenal for cancer therapy.

  2020cites this paper
• How Good is Jarzynski’s Equality for Computer-Aided Drug Design?

  2020cites this paper
• The Use of Conformational Restriction in Medicinal Chemistry.

  2019cites this paper
• Selective Small Molecule Myeloid Cell Leukemia-1 (MCL-1) Inhibitors: Novel Agents in Cancer Therapy

  2019influential citation
• Therapeutic inhibition of Mcl-1 blocks cell survival in estrogen receptor-positive breast cancers

  2019cites this paper
• MCL-1 inhibitors – where are we now (2019)?

  2019influential citation
• Discovery of β-carboline copper(II) complexes as Mcl-1 inhibitor and in vitro and in vivo activity in cancer models.

  2019cites this paper